These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3810519)

  • 21. An adverse drug reaction reporting program.
    Wasan SM; Marshall LB
    Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356
    [No Abstract]   [Full Text] [Related]  

  • 22. [Post-marketing surveillance of drugs: epidemiologic approach].
    Stanulović M; Jakovljević V; Sabo A
    Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
    [No Abstract]   [Full Text] [Related]  

  • 23. Critical reflection on the collection and evaluation of adverse drug reaction data.
    Venulet J
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
    [No Abstract]   [Full Text] [Related]  

  • 24. [Forms of information supplied by regional drug monitoring centers. Assessment of the activity during 1984].
    Lavarenne J; Evreux JC
    Therapie; 1986; 41(5):323-6. PubMed ID: 3810517
    [No Abstract]   [Full Text] [Related]  

  • 25. [Seventh French Drug Surveillance Seminar. Caen, 21-22 November 1985].
    Therapie; 1986; 41(5):323-84. PubMed ID: 3810518
    [No Abstract]   [Full Text] [Related]  

  • 26. [Is imputation in drug surveillance reliable?].
    Girard M
    Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
    [No Abstract]   [Full Text] [Related]  

  • 27. [Increased information role of a regional drug monitoring center].
    Elmalem J; Merigot P; Castot A; Lagier G; Efthymiou ML
    Therapie; 1986; 41(5):379-81. PubMed ID: 3810529
    [No Abstract]   [Full Text] [Related]  

  • 28. [6th French seminar on drug surveillance. Clermont-Ferrand, 22-23 November 1984].
    Therapie; 1985; 40(5):287-376. PubMed ID: 4095682
    [No Abstract]   [Full Text] [Related]  

  • 29. Rhode Island physicians' recognition and reporting of adverse drug reactions.
    Scott HD; Rosenbaum SE; Waters WJ; Colt AM; Andrews LG; Juergens JP; Faich GA
    R I Med J (1976); 1987 Jul; 70(7):311-6. PubMed ID: 3476980
    [No Abstract]   [Full Text] [Related]  

  • 30. Adverse drug reactions.
    Turner P
    Hum Toxicol; 1986 May; 5(3):161-2. PubMed ID: 3710492
    [No Abstract]   [Full Text] [Related]  

  • 31. [Regulatory guidelines and drug safety].
    Flury W
    Ther Umsch; 1993 Jan; 50(1):49-51. PubMed ID: 8378867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [How to assess the risk of drugs?].
    Roujeau JC
    Ann Dermatol Venereol; 1998 Oct; 125(10):673-5. PubMed ID: 9835953
    [No Abstract]   [Full Text] [Related]  

  • 33. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible strategies for early recognition of potential drug safety problems.
    Venulet J
    Adverse Drug React Acute Poisoning Rev; 1988; 7(1):39-47. PubMed ID: 3389236
    [No Abstract]   [Full Text] [Related]  

  • 35. [Handling by microcomputer of information requests at the Centre Régional de Pharmacovigilance, Paris-Saint-Antoine].
    Hamel JD; Biour M; Weissenburger J; Cheymol G
    Therapie; 1985; 40(5):325-7. PubMed ID: 4095689
    [No Abstract]   [Full Text] [Related]  

  • 36. [Drug surveillance as seen by the general practitioner. Apropos of a survey of 4175 physicians].
    Begaud B; Haramburu F; Péré JC; Delmas N; Lorson B; Albin H
    Therapie; 1984; 39(5):453-7. PubMed ID: 6506000
    [No Abstract]   [Full Text] [Related]  

  • 37. [Cost/benefit analysis of a regional drug surveillance center].
    Mignot G; Chichmanian RM; Spreux A; Bernard G
    Therapie; 1988; 43(5):377-8. PubMed ID: 3147546
    [No Abstract]   [Full Text] [Related]  

  • 38. [Chemical surveillance in the industrial environment].
    Conso F
    Rev Prat; 1987 Apr; 37(23):1321-5. PubMed ID: 3602879
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug interaction microcomputer software evaluation: Drug Therapy Screening System (DTSS).
    Poirier TI; Giudici RA
    Hosp Pharm; 1990 Aug; 25(8):738-41, 744. PubMed ID: 10170582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Activities of a regional drug monitoring center. What to evaluate, how and for what purpose].
    Péré JC; Haramburu F; Bégaud B; Barat C; Laborde B; Albin H
    Therapie; 1987; 42(4):351-8. PubMed ID: 3686468
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.